A kind of crisaborole cream and preparation method thereof

By using the formula of aqueous phase and pH adjuster in Ceribro cream, the physical instability and skin irritation problems of existing creams are solved, and uniform, delicate and easy to apply products are prepared, which improves the preparation stability and clinical medication compliance.

CN115887355BActive Publication Date: 2024-11-15南京康川济医药科技有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211446507.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-18
Publication Date
2024-11-15
Estimated Expiration
2042-11-18

AI Technical Summary

Technical Problem

The existing preparations of Ceribrolo cream have problems such as physical instability, difficulty in cleaning, complex production process and strong skin irritation. They are especially prone to crystallization at high concentrations, which affects its clinical drug compliance and safety.

Method used

The formula of Ceriboro cream consisting of aqueous phase and pH regulators, including Ceriboro, solvent, emulsifier, oil phase, antioxidant, preservative and aqueous phase, is prepared by specific heating and stirring steps. Adjust pH to 4-7 to optimize the uniformity and skin-friendliness of the cream.

Benefits of technology

The prepared cream is uniform and delicate, easy to apply, fast onset, reduces skin irritation, and has good stability in industrial production, avoids crystallization and improves the physical stability and safety of the preparation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115887355B_ABST
    Figure CN115887355B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of pharmaceutical preparations, and specifically relates to a crisaborole cream and a preparation method thereof. The crisaborole cream for external use on skin provided by the present invention comprises crisaborole, a solvent, an emulsifier, an oil phase, an antioxidant, a preservative, an aqueous phase and a pH regulator, and the prepared cream is uniform and fine, the product is not easy to crystallize, it is easy to apply, takes effect quickly, has a good antipruritic effect, can improve the skin affinity of the cream and reduce the irritation to the skin, and is easy to industrialize.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to a crisaborole cream and a preparation method thereof. Background Art

[0002] Crisaborole is a phosphodiesterase-4 (PDE4) inhibitor. PDE4 is a key regulatory point for the production of inflammatory cytokines in atopic dermatitis (AD), and works mainly by degrading cyclic adenosine monophosphate. Crisaborole is a boron-containing small molecule anti-inflammatory drug, and its mechanism of action has not been fully elucidated. In July 2015, both key Phase III studies of crisaborole achieved primary and secondary endpoints. In October 2015, the first-line results of the long-term safety study of crisaborole showed that intermittent use of crisaborole for more than 12 months was well tolerated and safe.

[0003] Patent CN110464702 A discloses a crisaborole cream and a preparation method thereof, wherein the crisaborole ointment is prepared using a non-aqueous ointment matrix material to improve the solubility and preparation stability of crisaborole.

[0004] The marketed dosage form of crisaborole is a cream (trade name: EUCRISA), which needs to be administered twice a day. According to the characteristics of allergic dermatitis, long-term continuous administration has poor clinical compliance. The cream is mainly an oily matrix. The skin surface feels greasy after administration. It is difficult to clean after contact with clothing, etc., and the clinical medication compliance is poor. The production process of the cream is complicated. The drug preparation and subpackaging require heat treatment, and special packaging materials are required. Clisborole has a tendency to crystallize out of the cream preparation disclosed in US 2016 / 0318955 A1, especially when present in relatively high concentrations (e.g., 2%). This in turn may lead to physical instability of the preparation. Therefore, it is crucial to develop a stable, effective, and quality-controlled crisaborole topical preparation. Summary of the invention

[0005] The invention provides a criborole cream for external use on the skin and a preparation method thereof. The components include an aqueous phase and a pH regulator. The prepared cream is uniform and smooth, easy to apply, quick to take effect, and has a good antipruritic effect. The skin affinity of the cream can be improved and the irritation to the skin can be reduced. The cream is easy to industrialize and produce.

[0006] The present invention adopts the following technical scheme: a crisaborole cream, which comprises the following components in parts by weight: 1-3 parts of crisaborole, 4-5 parts of solvent, 10-30 parts of emulsifier, 5-10 parts of oil phase, 0.01-0.2 parts of antioxidant, 0.05-0.2 parts of preservative and 45-65 parts of water phase.

[0007] In some embodiments, the crisaborole cream comprises, by weight: 2 parts of crisaborole, 5 parts of solvent, 14-24 parts of emulsifier, 7-8 parts of oil phase, 0.05-0.15 parts of antioxidant, 0.1-0.15 parts of preservative and 49-60 parts of water phase.

[0008] In some embodiments, the emulsifier in the crisaborole cream is selected from one or more of glyceryl mono- and distearate, polysorbate, polyoxyethylene stearate, polyoxyethylene alkyl ether, polyethylene glycol stearate, glyceryl stearate, cetyl alcohol, stearyl alcohol, and poloxamer; preferably one or more of polyethylene glycol stearate, glyceryl mono- and distearate, and glyceryl stearate.

[0009] In some embodiments, the oil phase in the crisaborole cream is selected from one or more of liquid paraffin, solid paraffin, vaseline, dimethicone, fatty acid glycerides, lanolin, lecithin, squalane, stearic acid, hexadecanol, and octadecyl alcohol; preferably one or more of liquid paraffin, solid paraffin, and dimethicone; more preferably one or more of liquid paraffin and dimethicone.

[0010] In some embodiments, the antioxidant in the crisaborole cream is selected from one or more of disodium edetate, butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, and tert-butylhydroquinone; preferably one or more of disodium edetate, butylated hydroxytoluene, and tert-butylhydroquinone; more preferably one or more of disodium edetate or butylated hydroxytoluene.

[0011] In some embodiments, the preservative in the crisaborole cream is selected from one or more of ethyl paraben, parabens, phenol, benzyl alcohol, benzoic acid, etc.; preferably ethyl paraben or phenol; more preferably ethyl paraben.

[0012] In some embodiments, the aqueous phase in the crisaborole cream is selected from one or more of water, propylene glycol, diethylene glycol monoethyl ether, glycerol, and isopropanol; preferably one or more of water, propylene glycol, diethylene glycol monoethyl ether or glycerol; more preferably a combination of water, propylene glycol and diethylene glycol monoethyl ether.

[0013] In some embodiments, the solvent in the crisaborole cream is selected from one or more of ethanol, propylene glycol, glycerol, isopropanol, and benzyl alcohol; preferably one or more of propylene glycol or glycerol.

[0014] In some embodiments, the crisaborole cream further comprises a pH adjuster, and the pH adjuster is selected from one or more of sodium hydroxide, triethanolamine, and hydrochloric acid; preferably triethanolamine or sodium hydroxide. By adding the pH adjuster, the pH value of the crisaborole cream is adjusted to 4 to 7, and more preferably the pH value is adjusted to 5 to 6.

[0015] In some typical embodiments, the crisaborole cream comprises the following components by weight:

[0016]

[0017]

[0018] In some typical embodiments, the crisaborole cream comprises the following components by weight:

[0019]

[0020] The present invention also provides a method for preparing the crisaborole cream, comprising the following steps:

[0021] (a) weighing an emulsifier, an oil phase, an antioxidant and a preservative respectively, mixing them, and then heating them to 80° C.;

[0022] (b) dissolving the API in a solvent and keeping it at 50-55°C for later use;

[0023] (c) adding the mixture of step (a) to the aqueous phase under stirring, and adding the solution of step (b) when the temperature of the mixture is reduced to 55-60° C., and continuing stirring and cooling;

[0024] (d) cooling to room temperature, and adjusting the pH value to between 5 and 6 using a pH adjuster;

[0025] The beneficial effects of the present invention are as follows: the criborole cream for external use on skin provided by the present invention is uniform and fine, the product is not easy to crystallize, is easy to apply, has a quick onset of action, has a good antipruritic effect, can improve the skin affinity of the cream and reduce the irritation to the skin, and is easy to industrialize. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 The properties of Example 1 observed under an electron microscope;

[0027] Figure 2 The properties of Example 2 observed under an electron microscope;

[0028] Figure 3 The properties of Example 3 observed under an electron microscope;

[0029] Figure 4The rheological property change diagram of Example 2;

[0030] Figure 5 The rheological property change diagram of Example 3;

[0031] Figure 6 Graph showing changes in rheological properties of the reference preparation. Specific implementation plan

[0032] The present invention is further described below in conjunction with specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0033] Example 1

[0034] Recipe of cream 1

[0035]

[0036] Preparation process of cream 1:

[0037] (a) Weigh all ingredients in phase 1 and phase 2 separately, and then heat to 80°C;

[0038] (b) dissolve the API in propylene glycol and store at 50-55°C for later use;

[0039] (c) Add phase 1 to phase 2 under stirring. When the mixture temperature is about 55-60°C, add phase 3 and continue stirring to cool down.

[0040] (d) Cooling to room temperature and adjusting the pH value to about 5-6.

[0041] The morphology of the obtained cream was observed under an optical microscope, and the cream was placed at 40°C and 60°C for 10 days, then cooled to room temperature to observe the changes in the properties of the cream. Figure 1 and Table 1 below.

[0042] Example 2

[0043] Cream 2 recipe

[0044]

[0045] Preparation process of cream 2:

[0046] (a) Weigh all ingredients in phase 1 and phase 2 separately, and then heat to 80°C;

[0047] (b) dissolve the API in propylene glycol and store at 50-55°C for later use;

[0048] (c) Add phase 1 to phase 2 under stirring. When the mixture temperature is about 55-60°C, add phase 3 and continue stirring to cool down.

[0049] (d) Cooling to room temperature and adjusting the pH value to about 4-6.

[0050] The morphology of the obtained cream was observed under an optical microscope, and the cream was placed at 40°C and 60°C for 10 days, then cooled to room temperature to observe the changes in the properties of the cream. Figure 2 and Table 1 below.

[0051] Example 3

[0052] Cream 3 recipe

[0053]

[0054] Preparation process of cream 3:

[0055] (a) Weigh all ingredients in phase 1 and phase 2 separately, and then heat to 80°C;

[0056] (b) dissolving the API in glycerol and refrigerating at 50-55°C for later use;

[0057] (c) Add phase 1 to phase 2 under stirring. When the mixture temperature is about 55-60°C, add phase 3 and continue stirring to cool down.

[0058] (d) Cooling to room temperature and adjusting the pH value to about 5-6.

[0059] The morphology of the obtained cream was observed under an optical microscope, and the cream was placed at 40°C and 60°C for 10 days, then cooled to room temperature to observe the changes in the properties of the cream. Figure 3 and Table 1 below.

[0060] Table 1 Changes in properties of creams with different prescriptions

[0061]

[0062] Test Case

[0063] The self-made products prepared in the above examples, the commercially available crisaborole ointment (trade name: EUCRISA) and Example 3 in patent CN110464702A (hereinafter referred to as Comparative Example 1) were subjected to finished product characteristics, centrifugation, and thermal cycle tests. The results showed that the ointments of Examples 2 and 3 had uniform particle size distribution, were easy to spread, were non-irritating to the skin, and had stable physical properties. The results are as follows:

[0064]

[0065] Accelerated stability sampling was performed on the self-made products obtained in Examples 2-3 above, the commercially available crisaborole ointment (trade name: EUCRISA), and Comparative Example 1. Samples were taken in January, March, and June to test properties, content uniformity, and impurities. The results are shown in the table below.

[0066]

[0067] The results showed that: Examples 2 and 3 did not show any crystallization phenomenon under accelerated conditions for 6 months, and the content, maximum single impurity and total impurities were significantly lower than those of the reference preparation and Comparative Example 1, and the quality was better than that of the reference preparation and Comparative Example 1.

Claims

1. A crisaborole cream comprising the following components by weight: The pH regulator is selected from triethanolamine, and the pH value of the crisaborole cream is adjusted to 5-6.

2. A crisaborole cream comprising the following components by weight: The pH regulator is selected from triethanolamine, and the pH value of the crisaborole cream is adjusted to 5-6.

3. The preparation method of the crisaborole cream according to claim 1 or 2, comprising the following steps: (a) weighing an emulsifier, an oil phase, an antioxidant and a preservative respectively, mixing them, and then heating them to 80° C.; (b) dissolving the API in a solvent and keeping it at 50-55°C for later use; (c) adding the mixture of step (a) to the aqueous phase under stirring, and adding the solution of step (b) when the temperature of the mixture is reduced to 55-60° C., and continuing stirring and cooling; (d) When the temperature is lowered to room temperature, a pH adjuster is used to adjust the pH value to between 5 and 6.